강도 변조 방사선 치료(IMRT) 시장 예측(-2030년) : 방사선 유형, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Intensity Modulated Radiation Therapy Market is accounted for $2.2 billion in 2023 and is expected to reach $3.5 billion by 2030 growing at a CAGR of 6.8% during the forecast period. Intensity Modulated Radiation Therapy (IMRT) is a precise radiotherapy technique that adjusts radiation beam intensity across multiple angles. This allows targeted delivery of higher doses to cancerous tissue while minimizing exposure to surrounding healthy structures. IMRT's precision enhances treatment effectiveness and reduces side effects compared to conventional radiation therapy.

According to the American Cancer Society, in 2022, an estimated 1.9 million new cases of cancer were diagnosed in the U.S.

Market Dynamics:

Driver:

The rising prevalence of cancer worldwide

Cancer rates continue to surge worldwide, there is a heightened demand for advanced and precise treatment modalities. IMRT, with its ability to deliver targeted radiation doses while minimizing damage to surrounding healthy tissues, have emerged as a crucial technology in the oncology landscape. The rising prevalence of diverse cancer types, coupled with an aging population, underscores the need for effective and tailored therapies. This trend propels the adoption of IMRT as a key player in the comprehensive oncological care, positioning it as a vital solution in the evolving landscape of cancer treatment.

Restraint:

High treatment costs

IMRT's sophisticated technology, involving precise radiation delivery, specialized equipment, and skilled personnel, contributes to elevated treatment expenses. This financial burden may deter healthcare institutions and patients, particularly in regions with limited healthcare budgets or where reimbursement policies are insufficient. The threat intensifies as cost considerations may divert attention toward alternative, more cost-effective treatment options, impacting IMRT's market share.

Opportunity:

Personalized medicine integration

Tailoring treatments to individual patient characteristics, such as genetic makeup and tumor profiles, enhances the precision and effectiveness of IMRT. Personalized approaches allow for optimized treatment plans, minimizing side effects and improving outcomes. This synergy aligns with the broader trend in healthcare towards precision medicine, fostering a more patient-centric and targeted therapeutic approach. The ability of IMRT to seamlessly integrate with personalized medicine not only expands its applicability but also positions it at the forefront of cutting-edge oncological care, driving demand and market growth.

Threat:

Complexity of implementation

IMRT's intricate technology demands specialized training for healthcare professionals, including radiation oncologists and medical physicists, leading to a potential shortage of adequately skilled personnel. The sophisticated planning and delivery processes involved in IMRT require not only advanced equipment but also a nuanced understanding of treatment planning software. Integration of IMRT into existing healthcare systems necessitates substantial investments in infrastructure and continuous educational initiatives. Moreover, the learning curve for mastering IMRT techniques may hinder its swift and widespread adoption, particularly in regions with limited resources or healthcare disparities.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market. The crisis led to disruptions in healthcare services, delaying elective procedures, including non-urgent cancer treatments. Resource reallocation and prioritization of COVID-19-related care strained the availability of medical facilities for routine cancer therapies, affecting the adoption of IMRT. Moreover, economic challenges and healthcare budget constraints in the wake of the pandemic may have influenced investment decisions, potentially slowing down the market's growth. Despite these setbacks, the importance of IMRT in advanced cancer care continues to drive its recovery as healthcare systems adapt to the evolving post-pandemic landscape.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to have a lucrative growth. IMRT's precision in adjusting radiation beams allows for targeted delivery to breast tumors while minimizing exposure to surrounding healthy tissue. This results in enhanced treatment efficacy and reduced side effects compared to conventional radiation therapy. The demand for IMRT in breast cancer cases is driven by the rising incidence of breast cancer globally, coupled with the increasing preference for advanced and precise treatment modalities that contribute to improved outcomes and better quality of life for patients undergoing radiation therapy for breast cancer.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period. These healthcare institutions invest in state-of-the-art IMRT technology and infrastructure, ensuring access to advanced radiation therapies for patients. Hospitals collaborate with radiation oncologists and technologists to deliver precise and personalized IMRT treatments. The integration of IMRT within hospital settings enhances cancer care capabilities, allowing for targeted therapy delivery and minimizing side effects. As key stakeholders, hospitals contribute significantly to the growth and accessibility of IMRT in the broader healthcare landscape.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share, driven by advanced healthcare infrastructure, a high prevalence of cancer, and robust R&D activities. The region's well-established reimbursement policies and a strong focus on technological innovation contribute to widespread adoption. Moreover, increasing awareness about the benefits of IMRT among healthcare professionals and patients enhances its market presence. Collaboration between key market players and research institutions further solidifies North America's position, ensuring a continuous surge in demand for IMRT solutions to address the evolving needs of cancer treatment in the region.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the spice rum market and is projected to have the highest CAGR over the forecast period driven by increasing cancer prevalence, advancing healthcare infrastructure, and rising awareness of advanced treatment options. Countries like China, India, and Japan are at the forefront of this expansion, with growing investments in oncology care. The region's large patient pool, coupled with government initiatives to improve cancer treatment, creates a fertile ground for IMRT adoption.

Key players in the market

Some of the key players in Intensity Modulated Radiation Therapy market include Accuray Incorporated, Brainlab AG, Varian Medical Systems, Inc, Elekta AB, Hitachi, Ltd., IBA Worldwide, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, Raysearch Laboratories and Siemens Healthineers AG.

Key Developments:

In October 2023, Siemens Healthineers AG Partnered with RefleXion X to develop AI-powered solutions for optimizing IMRT treatment plans.

In June 2023, Elekta AB. acquired Monaco, a leading treatment planning software for IMRT and other modalities.

In November 2022, Accuray unveiled a strategic collaboration with Limbus AI to bolster adaptive radiotherapy solutions. This partnership marked a significant milestone in expanding Accuray's product portfolio, showcasing the company's commitment to advancing cutting-edge technologies in the field of radiotherapy.

Radiation Types Covered:

• Proton Radiation
• Electron Radiation
• Photon Radiation
• Carbon Ion Radiation
• Other Radiation Types

Applications Covered:

• Prostate Cancer
• Lung Cancer
• Breast Cancer
• Brain Cancer
• Gynecological Cancer
• Other Applications

End Users Covered:

• Hospitals
• Standalone Radiation Therapy Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Intensity Modulated Radiation Therapy Market, By Radiation Type

• 5.1 Introduction
• 5.2 Proton Radiation
• 5.3 Electron Radiation
• 5.4 Photon Radiation
• 5.5 Carbon Ion Radiation
• 5.6 Other Radiation Types

6 Global Intensity Modulated Radiation Therapy Market, By Application

• 6.1 Introduction
• 6.2 Prostate Cancer
• 6.3 Lung Cancer
• 6.4 Breast Cancer
• 6.5 Brain Cancer
• 6.6 Gynecological Cancer
• 6.7 Other Applications

7 Global Intensity Modulated Radiation Therapy Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Standalone Radiation Therapy Centers
• 7.4 Other End Users

8 Global Intensity Modulated Radiation Therapy Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Accuray Incorporated
• 10.2 Brainlab AG
• 10.3 Varian Medical Systems, Inc
• 10.4 Elekta AB
• 10.5 Hitachi, Ltd.
• 10.6 IBA Worldwide
• 10.7 Koninklijke Philips N.V.
• 10.8 Mevion Medical Systems
• 10.9 Mitsubishi Electric Corporation
• 10.10 Raysearch Laboratories
• 10.11 Siemens Healthineers AG